1 / 16

Bio Genies, Inc.

GTX-001 & GTX-002: A License To Cure?. Bio Genies, Inc. « …The 'holy grail' of autoimmune drugs -a small molecule compound taken orally that is as effective as targeted biologics. This compound would eclipse the currently biologic-driven autoimmune market. ».

trina
Download Presentation

Bio Genies, Inc.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. GTX-001 & GTX-002: A License To Cure? Bio Genies, Inc. «…The 'holy grail' of autoimmune drugs -a small molecule compound taken orally that is as effective as targeted biologics. This compound would eclipse the currently biologic-driven autoimmune market.» J. Amarshi, A. Ehrlich, T. Fadel, J. Park, S. Zeller Friday November 20th 2009

  2. IBD is the Manifestation of Chronic Inflammation of the GI Tract

  3. Unmet Needs Exist for Efficacious and Safe Therapies

  4. GTX-001/002 Target Two Different Pathways Associated with IBD

  5. The Optimal Drug for IBD is a Balancing Act

  6. Untreated/well-managed population Non-candidates for GTX Therapy Candidates for GTX Therapy GTX-001 and GTX-002 Target Different Potential Populations 2008 patient population (in thousands)

  7. GTX-002 is Projected to be More Profitable, Even with Small Market Share Assumptions: 10% Discount Rate, 90% Patient Retention Rate

  8. Pricing will be Driven by Comparable Therapies and Clinical Data

  9. A Positive Return on Investment is Forecasted for GTX-002 R Assumptions: 10% Discount Rate, 90% Patient Retention Rate

  10. Critical Milestones will Signal Continuation of GTX-002 Development

  11. Licensing of GTX-002 is Recommended *GTX-002 is preferable to GTX-001 based on drug profile and market analysis -NPV of 1-13$ Billion w/ 10% Mkt Share *GTX-002 value will be driven by efficacy and toxicity profile in specific patient population subsets *We recommend pursuing GTX-002 for the broad treatment of UC and CD

  12. References 1) Janeway’s Immunobiology, 2007 2) Goldstein et. al, Journal of Clinical Investigation 2003. 3) Mowat, AM. Nature Rev. Immuno. 2003. 4) MacDonald et. al, J. Clin. Pathol. 1990. 5) www.clinical trials.gov 6) M. Karin, A. Lin, Nature Rev. Immunology, 2002 7) M, Karin, Y. Yamammoto, Q.M. Wang, Nature Rev. Drug Discovery, 2004 8) http://www.reuters.com/article/pressRelease/idUS145077+30-Jun-2009+MW20090630

  13. Additional Slides

  14. Financial Analysis

  15. Future Drugs on the Horizon

  16. Clinical Study Considerations

More Related